Loading

China IIT workshop

18 Jan 2027
Indigo B
Workshop
How to successfully set up, conduct, and leverage the data from Investigator-Initiated Trials (IITs) in China? Learning lessons from real-world experiences.

Strategic insights, case studies and audience Q&A – dissecting real-world experiences and clarifying the risks, benefits and key considerations to inform your assessment of whether a clinical study in China is the right option for your company and product candidate.
• What is the reality versus the perception in terms of: Evolving regulatory pathways in China? Relative cost and time to result? Acceptability of Chinese clinical data to other regulatory jurisdictions? Manufacturing trial material? Ethical oversight? Quality systems? Long-term follow-up requirements? Considerations in moving your clinical programme from China to other regions? Pathway to eventual global registration and commercialisation?
                                                                                                                                                                                                  
 
Speakers
Dr Eugene Jiaxian Wang, Founder & CEO - HELP Therapeutics
Dr Andrew Lee, Co-Founder & CEO - Spot Biosystems
Dr Jianhua Feng, Director, Department of Pediatrics - Zhejiang University School of Medicine

Topic

Clinical Development & Regulatory Strategy,Global Markets & International Development

Persona

Biotech,Clinicians,Regulators & Policy Makers